title: Challenges in the management of stage II colon cancer.
abstract: Approximately one third of patients diagnosed with early-stage colon cancer will present with lymph node involvement (stage III) and about one quarter with transmural bowel wall invasion but negative lymph nodes (stage II). Adjuvant chemotherapy targets micrometastatic disease to improve disease-free (DFS) and overall survival (OS). While beneficial for stage III patients, the role of adjuvant chemotherapy is unestablished in stage II disease. This likely relates to the improved outcome of these patients, and the difficulties in developing studies with sufficient power to document benefit in this patient population. However, recent investigation also suggests that molecular differences may exist between stage II and III cancers and within stage II patients. Validated pathologic prognostic markers are useful at identifying stage II patients at high risk for recurrence for whom the benefit from adjuvant chemotherapy may be greater. Such high-risk features include higher T stage (T4 v T3), suboptimal lymph node retrieval, presence of lymphovascular invasion, bowel obstruction, or bowel perforation, and poorly differentiated histology. However, for the majority of patients who do not carry any of these adverse features and are classified as "average-risk" stage II patients, the benefit of adjuvant chemotherapy remains unproven. Emerging understanding of the underlying biology of stage II colon cancer has identified molecular markers that may change this paradigm and improve our risk assessment and treatment choices for stage II disease. Assessment of microsatellite stability (MSI), which serves as a marker for DNA mismatch repair (MMR) system function, has emerged as a useful tool for risk stratification of patients with stage II colon cancer. Patients with high frequency of MSI have been shown to have increased OS and limited benefit from 5-fluorouracil (5-FU)-based chemotherapy. Additional research is necessary to clearly define the most appropriate way to use this marker and others in routine clinical practice.
authors.affiliation: Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA. efrat.dotan@fccc.edu
authors.forename: Efrat
authors.initials: E
authors.lastname: Dotan
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Cohen
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002277:Carcinoma / Q000235:genetics / Q000473:pathology* / Q000628:therapy*; D002887:Chromosomes, Human, Pair 18; D003110:Colonic Neoplasms / Q000235:genetics / Q000473:pathology* / Q000628:therapy*; D020869:Gene Expression Profiling; D005819:Genetic Markers / Q000235:genetics / Q000502:physiology; D006801:Humans; D019656:Loss of Heterozygosity / Q000502:physiology; D008495:Medical Oncology / Q000379:methods* / Q000592:standards; D053842:Microsatellite Instability; D009367:Neoplasm Staging
chemical_list: D005819:Genetic Markers